title: Topical Application of Interleukin-28A Attenuates Allergic Conjunctivitis in an Ovalbumin-Induced Mouse Model.
abstract: OBJECTIVE
  Allergic conjunctivitis (AC) is an immunoglobulin E (IgE)-mediated and helper T cell 2 (Th2)--cell-mediated disease characterized by conjunctival eosinophilic infiltration. Previous study shows that IL-28A had anti-allergic activity in airway disease. In this study, we examined the effect of IL-28A on a mouse model of ovalbumin (OVA)-induced experimental allergic conjunctivitis (EAC).
  
  
  METHODS
  Mouse EAC was induced by topical application of OVA after intraperitoneal (IP) sensitization with OVA in aluminum hydroxide (ALUM). Interleukin-28A was administered 1 hour before OVA challenge. Allergic conjunctivitis symptoms, eosinophil infiltration in the conjunctiva, antigen-specific IgE in the serum, and Th2 cytokine production by lymph node cells and splenocytes were subsequently analyzed.
  
  
  RESULTS
  Topical application of IL-28A to OVA-induced EAC reduced clinical symptoms, serum OVA-specific IgE, and the infiltration of eosinophils in the conjunctiva. In addition, topical administration of IL-28A suppressed the expression of IL-4, IL-5, and IL-13 (Th2-type cytokine) but promoted the expression of IFN-γ (Th1-type cytokine) by splenocytes and cervical lymph node cells in EAC mice. Immunofluorescence staining showed decrease expression of IL-4 and IL-5 in IL-28A-treated EAC conjunctiva.
  
  
  CONCLUSIONS
  Interleukin-28A shows therapeutic potential for allergic conjunctival inflammation.
authors.forename: Jianping
authors.initials: J
authors.lastname: Chen
authors.forename: Jing
authors.initials: J
authors.lastname: Zhang
authors.forename: Ruijuan
authors.initials: R
authors.lastname: Zhao
authors.forename: Jiayi
authors.initials: J
authors.lastname: Jin
authors.forename: Ying
authors.initials: Y
authors.lastname: Yu
authors.forename: Weihua
authors.initials: W
authors.lastname: Li
authors.forename: Wencong
authors.initials: W
authors.lastname: Wang
authors.forename: Hongyan
authors.initials: H
authors.lastname: Zhou
authors.forename: Shao Bo
authors.initials: SB
authors.lastname: Su
mesh_terms: D000287:Administration, Topical; D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000097:blood / Q000276:immunology; D002478:Cells, Cultured; D003228:Conjunctiva / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D003233:Conjunctivitis, Allergic / Q000139:chemically induced / Q000188:drug therapy* / Q000276:immunology; D004195:Disease Models, Animal; D004797:Enzyme-Linked Immunosorbent Assay; D004804:Eosinophils / Q000473:pathology; D005260:Female; D007073:Immunoglobulin E / Q000276:immunology; D007150:Immunohistochemistry; D007378:Interleukins / Q000008:administration & dosage*; D051379:Mice; D008807:Mice, Inbred BALB C; D010047:Ovalbumin / Q000633:toxicity; D013601:T-Lymphocytes / Q000276:immunology / Q000473:pathology; D000095022:Interferon Lambda
chemical_list: D000888:Antibodies, Anti-Idiotypic; D007073:Immunoglobulin E; D007378:Interleukins; D010047:Ovalbumin; C000594666:IL28A protein, mouse; D000095022:Interferon Lambda